The unprecedented convergence of multi-modal data, advanced disease modeling, and computational power is revolutionizing drug discovery. insitro is harnessing this moment to redefine how medicines are developed for complex diseases. Our AI/ML-enabled platforms integrate and scale data to rapidly discover novel biological insights to redefine complex diseases and identify new targets and drugs.
Reporting to the VP of Strategy and Corporate Development, we seek a results-oriented business development leader with a strong track record in asset licensing and technology collaborations. You will be responsible for shaping strategies and transactions that drive insitro's growth and impact. If you are a creative thinker passionate about the power of data and compute to change medicine, we encourage you to apply.
This role is based in South San Francisco, with a hybrid approach of at least 3 days per week in the office and the option for the other 1-2 days working from home.
As the Director of Corporate Development and External Innovation, you will play a pivotal role in shaping insitro's growth and impact by identifying, evaluating, and executing strategic external partnerships and licensing opportunities. Your focus will be to deeply understand the objectives, challenges, and opportunities prioritized by our key scientific teams and leaders. Leveraging this understanding, you will be leading buy-side and sell-side prosecution of asset licensing opportunities across disease areas, including comprehensive landscaping, term sheet development and negotiation. Additionally, you will own the development and execution of technology partnering strategies to drive value for insitro. This will involve both partnering insitro's capabilities externally as well as evaluation and incorporation of external technologies into instiro.
This is an exceptional opportunity for a highly motivated individual who is passionate about the intersection of advanced science and strategic business development, and eager to contribute to the discovery of life-changing therapies for patients. You will leverage your expertise in drug discovery, external innovation and partnering to drive significant value for insitro and its mission to bring better drugs faster to the patients who can benefit most.
About You:
Compensation & Benefits at insitro:
Our target starting salary for successful US-based applicants for this role is $213,000 - $240,000. To determine starting pay, we consider multiple job-related factors including a candidate's skills, education and experience, market demand, business needs, and internal parity. We may also adjust this range in the future based on market data.
This role is eligible for participation in our Annual Performance Bonus Plan (based on company targets by role level and annual company performance) and our Equity Incentive Plan, subject to the terms of those plans and associated policies.
In addition, insitro also provides our employees:
insitro is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.
We believe diversity, equity, and inclusion need to be at the foundation of our culture. We work hard to bring together diverse teams–grounded in a wide range of expertise and life experiences–and work even harder to ensure those teams thrive in inclusive, growth-oriented environments supported by equitable company and team practices. All candidates can expect equitable treatment, respect, and fairness throughout the interview process.
Please be aware of recruitment scams: we never request payments, all recruitment communications are from @insitro.com, and if in doubt, contact us at info@insitro.com.
About insitro
insitro is a drug discovery and development company using machine learning (ML) and data at scale to decode biology for transformative medicines. At the core of insitro’s approach is the convergence of in-house generated multi-modal cellular data and high-content phenotypic human cohort data. We rely on these data to develop ML-driven, predictive disease models that uncover underlying biologic state and elucidate critical drivers of disease. These powerful models rely on extensive biological and computational infrastructure and allow insitro to advance novel targets and patient biomarkers, design therapeutics and inform clinical strategy. insitro is advancing a wholly owned and partnered pipeline of insights and therapeutics in neuroscience, oncology and metabolism. Since launching in 2018, insitro has raised over $700 million from top tech, biotech and crossover investors, and from collaborations with pharmaceutical partners. For more information on insitro, please visit www.insitro.com.
Read Full Description